Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2018 - 2019)

Historic Long-Term Deferred Tax for Akebia Therapeutics (AKBA) over the last 2 years, with Q4 2019 value amounting to $109.4 million.

  • Akebia Therapeutics' Long-Term Deferred Tax fell 303.7% to $109.4 million in Q4 2019 from the same period last year, while for Dec 2019 it was $109.4 million, marking a year-over-year decrease of 303.7%. This contributed to the annual value of $109.4 million for FY2019, which is 303.7% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Long-Term Deferred Tax of $109.4 million as of Q4 2019, which was down 303.7% from $112.8 million recorded in Q4 2018.
  • In the past 5 years, Akebia Therapeutics' Long-Term Deferred Tax registered a high of $112.8 million during Q4 2018, and its lowest value of $109.4 million during Q4 2019.